The following drug interactions have not been reported in clinical trials with azithromycin; however, no specific drug interaction studies have been performed to evaluate potential drug-drug interaction. Nonetheless, they have been observed with macrolide products. Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin? elevated digoxin levels. Ergotamine or dihydroergotamine? acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia. Triazolam? decrease the clearance of triazolam and thus may increase the pharmacologic effect of triazolam. Drugs metabolized by the cytochrome P 450 system? elevations of serum carbamazepine, cyclosporine, hexobarbital, and phenytoin levels. Laboratory Test Interactions: There are no reported laboratory test interactions. Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse lymphoma assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay. | ||||
Email this article
Printer friendly
Bookmark this pageadvertisement
